BioPorto A/S (BIOPOR.CO)
| Previous close | 2.2200 |
| Open | 2.2600 |
| Bid | 2.2600 x 0 |
| Ask | 2.2650 x 0 |
| Day's range | 2.2400 - 2.2750 |
| 52-week range | 1.2000 - 3.8500 |
| Volume | |
| Avg. volume | 1,038,951 |
| Market cap | 973.173M |
| Beta (5Y monthly) | 1.21 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1500 |
| Earnings date | 15 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswireBioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo
July 26, 2024 News Release BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo ADLM 2024 Conference – Chicago, July 26, 2024 – BioPorto Diagnostics, a company specializing in in vitro diagnostics with an emphasis on the early detection of Acute Kidney Injury (AKI), will be participating in the Association for Diagnostics and Laboratory Medicine (ADLM) 2024 clinical lab expo. BioPorto will feature its FDA-cleared product designed for pediatric AKI risk assessment,
GlobeNewswirePreliminary data suggests potential use beyond early AKI diagnosis for NGAL biomarker
July 17, 2024 News Release Preliminary data suggests potential use beyond early AKI diagnosis for NGAL biomarker COPENHAGEN, Denmark and BOSTON, MA, USA, July 17, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), recently received marketing clearance by the US Food and Drug Administration (FDA) for ProNephro AKI™ (NGAL) for risk assessment of moderate-to-severe acute ki
- Globe Newswire
Results from Clinical Studies Highlight the Efficacy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Acute Kidney Injury
July 11, 2024 News Release Results from Clinical Studies Highlight the Efficacy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Acute Kidney Injury COPENHAGEN, Denmark and BOSTON, MA, USA, July 11, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), received marketing clearance by the US Food and Drug Administration (FDA) for ProNephro AKI™ (NGAL) for r
